Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
Researchers finding that microRNA can potentially regrow 90% of lost hair, and the challenges involved in moving this research forward to human trials. Various treatments for hair loss, such as finasteride and minoxidil, have been discussed.
User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regeneration therapy, stem cell therapy, exosome therapy, and dermal exosomes provided.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
The conversation is about someone seeking advice on the best microneedling device to use for hair loss, mentioning pens, stamps, and rollers as options.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
The conversation is about a user experiencing a tingling sensation and redness on their scalp, possibly related to hair loss treatments. Suggestions include using Nizoral shampoo and consulting a dermatologist, while the user mentions using oral finasteride.
A user discusses their experience with at-home microneedling at 1mm for hair growth, feeling like they're hitting their skull. Other users suggest lowering the needle depth or stopping due to discomfort.
A user recently started using nanoxidil 5% for hair loss, particularly on the hairline, and is seeking feedback or experiences from others. The conversation focuses on the effectiveness of nanoxidil.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
A 16-year-old female experiencing severe hair loss and sebum buildup, likely due to telogen effluvium and PCOS, is currently using vitamin D3 supplements, Redenser serum, and T follihair supplements. Recommendations include addressing PCOS first and consulting a doctor.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
The conversation discusses whether a longtime NW7 scalp has vellus hairs under a microscope or is completely smooth. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The user has been using finasteride and minoxidil for hair loss and recently added microneedling and biotin vitamins to their routine. They are asking if microneedling can regrow hair in completely bald areas, specifically around the temples and above/in front of the ears.
Microneedling stimulates hair growth through stem cell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
Microneedling does not prevent future hair transplants, but some surgeons report the skin becomes "harder" in treated areas. There is no clear evidence to confirm this effect.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.
A 35-year-old man with 10 years of hair loss at NRW7 started using topical Minoxidil and noticed some hair regrowth. He plans to continue with Minoxidil, add microneedling, and possibly try topical treatments like finasteride or dutasteride.